YWYe Wu

Ye Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ye Wu has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Xin Luan

    State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    9 shared publications
  • Wei-Dong Zhang

    School of Pharmacy, Naval Medical University, Shanghai, China

    6 shared publications
  • Jiayi Lin

    State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

    5 shared publications
  • Shengxin Lu

    State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    5 shared publications
  • Dale George Nagle

    Shanghai Jiao Tong University, Shanghai, PR China

    4 shared publications
  • Xiaokun Zhang

    State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    4 shared publications

Latest Publications

  • A GSH-responsive stapled oncolytic peptide-STING agonist conjugate for tumor-selective immunotherapy

    by Xin Sun, Shengxin Lu, Rui Liang, Xiaokun Zhang, Zhixiang Xu, Zhan Wang, Xuelin Sun, Xin Luan, Ye Wu

  • Naturally derived oncolytic peptides: from discovery to clinical translation

    by Jiyuan Zhang, Yi Chen, Shengxin Lu, Xiaokun Zhang, Guanrunze Yang, Zhidan Zhang, Ye Wu, Xuemei Zhang, Weidong Zhang

  • Open Access

    Mechanism‐Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy

    by Wen Zhang, Shengxin Lu, Guangyong Zheng, Shensuo Li, Hongyu Chen, Mei Hong, Xiangru Zhou, Ruotian Tang, Ye Wu, Weidong Zhang, et al.

    Oncolytic peptides (OPs) represent a promising class of cancer therapeutics capable of rapidly lysing tumor cells and activating antitumor immunity. However, accurate in silico identification of potent OPs remains challenging due to limited datasets and high false‐positive rates. Here, we present MISPOP (Mechanism‐Informed Screening Pipeline for Oncolytic Peptides), an integrated machine learning framework that combines eXtreme Gradient Boosting, deep neural networks, and transfer learning into a high‐confidence ensemble model augmented with physicochemical priors. Applied to a natural peptide library of 1033 sequences, MISPOP prioritized 16 candidates, among which five were synthesized and evaluated across three tumor cell lines. Dermaseptin‐S9 exhibited the most favorable therapeutic index. Molecular dynamics simulations revealed its deep insertion into lipid bilayers and stable peptide‐membrane interactions, while in vitro assays confirmed pronounced membrane disruption and induction of immunogenic cell death. In a B16F10 melanoma model, Dermaseptin‐S9 achieved over 92% tumor growth inhibition without evident systemic toxicity. Collectively, these findings demonstrate that embedding biochemical priors into ensemble learning can markedly improve predictive accuracy and enable the discovery of potent OPs, offering a generalizable paradigm for accelerating peptide‐based oncotherapy development.


  • Hypoxia-responsive oncolytic conjugate triggers type-II immunogenic cell death for enhanced photodynamic immunotherapy

    by Maomao Ren, Xin Sun, Jiayi Lin, Yajie Kan, Shengxin Lu, Xiaokun Zhang, Rui Liang, Bei Wang, Hongzhuan Chen, Ye Wu, et al.


  • Open Access

    In Silico Discovery of Stapled Peptide Inhibitor Targeting the Nur77‐PPARγ Interaction and Its Anti‐Breast‐Cancer Efficacy

    by Huiting Bian, Xiaohui Liang, Dong Lu, Jiayi Lin, Xinchen Lu, Jinmei Jin, Lijun Zhang, Ye Wu, Hongzhuan Chen, Weidong Zhang, et al.

    The binding of peroxisome proliferator‐activated receptor γ (PPARγ) to the orphan nuclear receptor Nur77 facilitates the ubiquitination and degradation of Nur77, and leads to aberrant fatty acid uptake for breast cancer progression. Because of its crucial role in clinical prognosis, the interaction between Nur77 and PPARγ is an attractive target for anti‐breast‐cancer therapy. However, developing an inhibitor of the Nur77‐PPARγ interaction poses a technical challenge due to the absence of the crystal structure of PPARγ and its corresponding interactive model with Nur77. Here, ST‐CY14, a stapled peptide, is identified as a potent modulator of Nur77 with a KD value of 3.247 × 10−8 M by in silico analysis, rational design, and structural modification. ST‐CY14 effectively increases Nur77 protein levels by blocking the Nur77‐PPARγ interaction, thereby inhibiting lipid metabolism in breast tumor cells. Notably, ST‐CY14 significantly suppresses breast cancer growth and bone metastasis in mice. The findings demonstrate the feasibility of exploiting directly Nur77‐PPARγ interaction in breast cancer, and generate what to the best knowledge is the first direct inhibitor of the Nur77‐PPARγ interaction available for impeding fatty acid uptake and therapeutic development.


  • Open Access

    Seleno-amino Acid Metabolism Reshapes the Tumor Microenvironment: from Cytotoxicity to Immunotherapy

    by Rui Liang, Aoyu Cheng, Shengxin Lu, Xiaokun Zhang, Maomao Ren, Jiayi Lin, Ye Wu, Weidong Zhang, Xin Luan

    Selenium (Se) is an essential trace element for biological processes. Seleno-amino acids (Se-AAs), known as the organic forms of Se, and their metabolic reprogramming have been increasingly recognized to regulate antioxidant defense, enzyme activity, and tumorigenesis. Therefore, there is emerging interest in exploring the potential application of Se-AAs in antitumor therapy. In addition to playing a vital role in inhibiting tumor growth, accumulating evidence has revealed that Se-AA metabolism could reshape the tumor microenvironment (TME) and enhance immunotherapy responses. This review presents a comprehensive overview of the current progress in multifunctional Se-AAs for antitumor treatment, with a particular emphasis on elucidating the crosstalk between Se-AA metabolism and various cell types in the TME, including tumor cells, T cells, macrophages, and natural killer cells. Furthermore, novel applications integrating Se-AAs are also discussed alongside prospects to provide new insights into this emerging field.


  • Open Access

    Crizotinib‐based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation

    by Jin‐Jiao Chen, Jin‐Mei Jin, Wen‐Jie Gu, Zeng Zhao, Hu Yuan, Yu‐Dong Zhou, Dale G. Nagle, Qiu‐Lei Xi, Xue‐Mei Zhang, Qing‐Yan Sun, et al.

    As one of the common malignant cancer types, gastric cancer (GC) is known for late‐stage diagnosis and poor prognosis. Overexpression of the receptor tyrosine kinase MET is associated with poor prognosis among patients with advanced stage GC. However, no MET inhibitor has been used for GC treatment. Like other tyrosine kinase inhibitors that fit the “occupancy‐driven” model, current MET inhibitors are prone to acquired resistance. The emerging proteolysis targeting chimera (PROTAC) strategy could overcome such limitations through direct degradation of the target proteins. In this study, we successfully transformed the MET‐targeted inhibitor crizotinib into a series of PROTACs, recruiting cereblon/cullin 4A E3 ubiquitin ligase to degrade the MET proteins. The optimized lead PROTAC (PRO‐6 E) effectively eliminated MET proteins in vitro and in vivo, inhibiting proliferation and motility of MET‐positive GC cells. In the MKN‐45 xenograft model, PRO‐6 E showed pronounced antitumor efficacy with a well‐tolerated dosage regimen. These results validated PRO‐6 E as the first oral PROTAC for MET‐dependent GC.


  • Open Access

    Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer

    by Jinmei Jin, Yaping Wu, Zeng Zhao, Ye Wu, Yu-Dong Zhou, Sanhong Liu, Qingyan Sun, Guizhu Yang, Jiayi Lin, Dale G. Nagle, et al.

    The aberrant activation of STAT3 is associated with the etiology and progression in a variety of malignant epithelial-derived tumors, including head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC). Due to the lack of an enzymatic catalytic site or a ligand-binding pocket, there are no small-molecule inhibitors directly targeting STAT3 that have been approved for clinical translation. Emerging proteolysis targeting chimeric (PROTAC) technology–based approach represents a potential strategy to overcome the limitations of conventional inhibitors and inhibit activation of STAT3 and downstream genes. In this study, the heterobifunctional small-molecule–based PROTACs are successfully prepared from toosendanin (TSN), with 1 portion binding to STAT3 and the other portion binding to an E3 ubiquitin ligase. The optimized lead PROTAC (TSM-1) exhibits superior selectivity, potency, and robust antitumor effects in STAT3-dependent HNSCC and CRC — especially in clinically relevant patient-derived xenografts (PDX) and patient-derived organoids (PDO). The following mechanistic investigation identifies the reduced expression of critical downstream STAT3 effectors, through which TSM-1 promotes cell cycle arrest and apoptosis in tumor cells. These findings provide the first demonstration to our knowledge of a successful PROTAC-targeting strategy in STAT3-dependent epithelial cancer.


  • Open Access

    Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer

    by Lu Lu, He Zhang, Yudong Zhou, Jiayi Lin, Weidong Gao, Ting Yang, Jinmei Jin, Lijun Zhang, Dale G. Nagle, Weidong Zhang, et al.

    Rationale: Scarce tumor mutation burden and neoantigens create tremendous obstacles for an effective immunotherapy of colorectal cancer (CRC). Oncolytic peptides rise as a promising therapeutic approach that boosts tumor-specific immune responses by inducing antigenic substances. However, the clinical application of oncolytic peptides has been hindered because of structural instability, proteolytic degradation, and undesired toxicity when administered systemically.


  • Open Access

    Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

    by Jiayi Lin, Jinmei Jin, Yiwen Shen, Lijun Zhang, Gang Gong, Huiting Bian, Hongzhuan Chen, Dale G. Nagle, Ye Wu, Weidong Zhang, et al.

    Classic small molecule inhibitors that directly target pathogenic proteins typically rely on the accessible binding sites to achieve prolonged occupancy and influence protein functions. The emerging targeted protein degradation (TPD) strategies exemplified by PROteolysis TArgeting Chimeras (PROTACs) are revolutionizing conventional drug discovery modality to target proteins of interest (POIs) that were categorized as “undruggable” before, however, these strategies are limited within intracellular POIs. The novel new degrader technologies such as LYsosome-TArgeting Chimaeras (LYTACs) and Antibody-based PROTACs (AbTACs) have been successfully developed to expand the scope of TPD to extracellular and membrane proteins, fulfilling huge unmet medical needs. Here, we systematically review the currently viable protein degradation strategies, emphasize that LYTACs and AbTACs turn a new avenue for the development of TPD, and highlight the potential challenges and directions in this vibrant field.